# OnCo record turning-point-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/turning-point-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "turning-point-therapeutics" ;
  schema:name "Turning Point Therapeutics"@en ;
  schema:alternateName "Turning Point Therapeutics, Inc."@en, "NASDAQ:TPTX"@en ;
  schema:description "Turning Point Therapeutics developed repotrectinib, a pill aimed at lung cancers and other tumours driven by ROS1 or NTRK gene changes. Bristol Myers Squibb bought the company in 2022."@en ;
  schema:url <https://onco.cc/companies/turning-point-therapeutics/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.sec.gov/Archives/edgar/data/1595893/000119312522166796/d344596dex991.htm>, <https://www.sec.gov/Archives/edgar/data/1595893/000119312522166807/d337235dex992.htm>, <https://www.sec.gov/Archives/edgar/data/1595893/000114036122029961/brhc10040812_8k.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/ros1/>, <https://onco.cc/targets/ntrk/> ;
  onco:drugs <https://onco.cc/drugs/repotrectinib/> .